Private Equity Hub -- ViroXis Corp. received a $2.5 million investment from the Texas Emerging Technology Fund. The capital will be used to advance development and commercialization of San Antonio, Texas-based ViroXis’ topical Albuterpenoid anti-viral treatment of skin warts. The investment was announced by Startech and the South Texas Regional Center of Innovation and Commercialization.
